The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001365358p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
7/10/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of Intense Pulsed Light (IPL) Treatment on Vascularity and Hypertrophic Scarring in Adult Burn Donor Sites
Scientific title
Effect of Intense Pulsed Light (IPL) on Vascularity and Hypertrophic Scar Development in Burn Donor Sites: A Randomised Controlled Trial Using Objective Imaging with the Antera 3D System
Additional trial identifiers [1] 318596 0
nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Burns Scar 343797 0
Condition category
Condition code
Injuries and Accidents 339934 339934 0 0
Burns

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention ( clinical trial )
Intense Pulsed Light (IPL) therapy applied to burn split-thickness skin graft donor-site scars. IPL is a light-based energy device that delivers pulses of broad-spectrum light to the skin. The light energy is absorbed by hemoglobin within blood vessels and converted to heat.

Who delivers it:
IPL treatment will be delivered by appropriately trained and credentialled clinicians within the Victorian Adult Burns Service.

How it is delivered:
Individual, face-to-face treatment. One donor-site area will receive IPL in addition to standard scar management, while a comparable donor-site area will receive standard scar management alone as the intra-subject control. Each treatment session will take approximately 10 to 20 minutes.

Frequency and duration:
Three IPL treatment sessions will be administered approximately 8 weeks apart, commencing 12 weeks after complete epithelialisation. Participants will be followed for 12 months after the final treatment session.

Where:
IPL treatment will be performed in the theatre/day procedure setting at The Alfred Hospital. Scar assessments and follow-up will be undertaken through the Victorian Adult Burns Service.

Adherence:
Attendance at treatment and follow-up appointments will be monitored. Participants will receive instructions regarding standard scar management and aftercare, with adherence discussed at follow-up visits. Appointment reminders will occur through usual hospital processes.

Aftercare:
Standard burn scar management and aftercare will be provided in accordance with routine clinical practice. This may include moisturising, massage, movement exercises, pressure therapy, and skin protection measures, as clinically indicated.
Intervention code [1] 335503 0
Treatment: Devices
Intervention code [2] 335734 0
Treatment: Other
Description of the comparator or control
Comparator: Standard scar management alone, without IPL treatment. This will include routine moisturising, scar massage, silicone therapy and sun protection, with compression therapy where clinically indicated.
Who delivers it: Standard scar management will be provided and supported by appropriately trained members of the Victorian Adult Burns Service clinical team.
How it is delivered: Individual, face-to-face care, with participants continuing their usual scar management at home.
Frequency and duration: three 10-20 mins treatment sessions commencing 12 weeks after complete epithelialisation Standard scar management will continue throughout the study period, from baseline through to the 12-month follow-up after the final IPL treatment.
Where: Scar management education which includes, hydration with moisturising, massage, silicone therapy and assessment will occur through the Victorian Adult Burns Service. Participants will undertake routine scar care at home as above included in scar management education and also SPF protection
Adherence: Adherence to standard scar management will be discussed and monitored during study assessments and follow-up appointments. Participants will receive usual clinical instructions and appointment reminders.
Control group
Active

Outcomes
Primary outcome [1] 347102 0
Change in scar vascularity, objectively measured by haemoglobin concentration using the Antera 3D imaging system.
Timepoint [1] 347102 0
12 months following the final IPL treatment. This allows assessment of the longer-term effect of IPL on scar vascularity.
Secondary outcome [1] 468949 0
Scar quality – measured using the Patient and Observer Scar Assessment Scale (POSAS) 3.0.
Timepoint [1] 468949 0
Assessment at baseline (12 weeks following complete epithelialisation) and at 3, 6 and 12 months following the final IPL treatment.
Secondary outcome [2] 470436 0
Health-related quality of life
Timepoint [2] 470436 0
Baseline (prior to treatment), before each treatment session, and at follow-up assessments up to 12 months after the final treatment session.

Eligibility
Key inclusion criteria
Adults aged 18 years or older.
Patient receiving care through the Victorian Adult Burns Service.
Healed split-thickness skin graft (STSG) donor site 12 weeks to 12 months following complete epithelialisation.
Evidence of increased vascularity and active scar remodelling or early hypertrophic scarring.
Fitzpatrick skin type III–VI.
Two comparable donor-site areas within the same anatomical region suitable for intra-subject comparison.
Able to provide informed consent and comply with study treatment and follow-up requirements
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Age under 18 years.
Unable to provide informed consent or comply with study requirements.
Fitzpatrick skin type I–II.
Mature donor-site scar without evidence of active remodelling.
Previous scar-directed treatment to the study area, including laser, IPL, corticosteroid injection, microneedling or surgical revision.
Active wound breakdown or infection.
Dermatological conditions affecting pigmentation, vascularity or wound healing.
Photosensitivity disorders or use of relevant photosensitising medications.
Pregnancy or breastfeeding.
Skin malignancy within the treatment area.
Unable to obtain reliable Antera 3D imaging or attend required follow-up.
Any other clinical condition making IPL treatment unsuitable or likely to affect study outcomes

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
To be confirmed with the research/PowerTrials team prior to study commencement.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence with 1:1 allocation of the two comparable donor-site areas to IPL treatment or standard scar management.
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 30330 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 46743 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 323170 0
Hospital
Name [1] 323170 0
The Alfred Hospital
Country [1] 323170 0
Australia
Primary sponsor type
Hospital
Name
The Alfred Hospital
Address
Country
Australia
Secondary sponsor category [1] 326138 0
None
Name [1] 326138 0
Address [1] 326138 0
Country [1] 326138 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 321576 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 321576 0
Ethics committee country [1] 321576 0
Australia
Date submitted for ethics approval [1] 321576 0
20/11/2026
Approval date [1] 321576 0
Ethics approval number [1] 321576 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154130 0
Mrs Sally NG
Address 154130 0
The Alfred Hospital 55 Commercial Road, Melbourne, VIC 3004
Country 154130 0
Australia
Phone 154130 0
+61 427020784
Fax 154130 0
Email 154130 0
Contact person for public queries
Name 154131 0
Sally NG
Address 154131 0
The Alfred Hospital 55 Commercial Road, Melbourne, VIC 3004
Country 154131 0
Australia
Phone 154131 0
+61 427020784
Fax 154131 0
Email 154131 0
Contact person for scientific queries
Name 154132 0
Sally NG
Address 154132 0
The Alfred Hospital 55 Commercial Road, Melbourne, VIC 3004
Country 154132 0
Australia
Phone 154132 0
+61 427020784
Fax 154132 0
Email 154132 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval  [email protected]


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.